Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
Related Posts
Popular News
Latest News
Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.
Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both...
Arkham data shows Bitmine sending 9,600 ETH to Coinbase Prime
Blockchain data shows that crypto treasury firm BitMine Immersion Technologies recently transferred around 9,600 ETH to wallets linked to Coinbase’s...
‘I promised my parents’: I take care of my brother who is developmentally disabled. I’m now retired. Am I doing enough?
“I have $560,000 in my IRA, $125,000 in stocks and $50,000 in savings.”
Anthropic files lawsuit against US government over supply chain risk label
Anthropic is suing the US Department of Defense and other federal bodies after being designated as “supply chain risk” by...
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.